Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: A retrospective review of 40 patients

American Journal of Hematology

Volumn 83, Issue 2, 2008, Pages 122-125

  Spahr, Joseph E ^a,b   Rodgers, George M ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; RITUXIMAB; STEROID; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTICOAGULATION; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; CLINICAL ARTICLE; CONTINUOUS INFUSION; FEMALE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET COUNT; PLATELET TRANSFUSION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES;

EID: 38349107396     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21060     Document Type: Article

References (32)

1. Chandramouli NB, Rodgers GM. Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia. Am J Hematol 2000;65:85-86.
2. Jolles S, Sewell WA, Misbah SA, et al. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005;142:1-11.
3. Ballow M, Shoenfeld Y, Katz U, et al. Clinical and investigational considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005;62(16 Suppl 3):S12-S18; quiz S19-S21.
4. Gill V, Doig C, Knight D, et al. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005;112:2031-2039.
5. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(4 Suppl):S525-S553.
6. Leytin V, Mykhaylov S, Starkey AF, et al. Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol 2006;133:78-82.
7. Webster ML, Sayeh E, Crow M, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPII-bIIIa versus GPIbα antibodies. Blood 2006;108:943-946.
8. Bierling P, Godeau B. Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on. Vox Sang 2004;86:8-14.
9. Shah S, Ballow M, Shoenfeld Y, et al. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005;62(16 Suppl 3):S5-S11.
10. Junghans RP, Ahn YS. High-dose intravenous γ-globulin to suppress alloimmune destruction of donor platelets. Am J Med 1984;76:204-208.
11. Baumann MA, Menitove JE, Aster RH, et al. Urgent treatment of idiopathic thrombocytopenic purpura with single-dose γ-globulin infusion followed by platelet transfusion. Ann Intern Med 1986;104:808-809.
12. Pacetti P, Garau D, Caramatti C, et al. Assessment of the efficacy of a last-generation polyvalent immunoglobulin in the treatment of idiopathic thrombocytopenic purpura. Curr Med Res Opin 1997;13:517-527.
13. Godeau B, Caulier MT, Decuypere L, et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: Results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 1999;107:716-719.
14. Choi CW, Kim BS, Seo JH, et al. Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. Am J Hematol 2001;66:197-202.
15. Altintop L, Albayrak D. Oral high-dose methylprednisolone and intravenous immunoglobulin treatments in adult chronic idiopathic thrombocytopenic purpura. Am J Hematol 1997;56:191-192.
16. Schiavotto C, Ruggeri M, Rodeghiero F. Failure of repeated courses of high-dose intravenous immunoglobulin to induce stable remission in patients with chronic idiopathic thrombocytopenic purpura. Ann Hematol 1995;70:89-90.
17. Mathew TC, Vasudevan R, Leb L, et al. Coronary artery bypass grafting in immune thrombocytopenic purpura. Ann Thorac Surg 1997;64:1059-1062.
18. Godeau B, Lesage S, Divine M, et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993;82:1415-1421.
19. Brenner B. Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous γ-globulin. Clin Exp Rheumatol 1996;14(Suppl 15):S115-S119.
20. Rodeghiero F, Schiavotto C, Castaman G, et al. A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. Haematologica 1992;77:248-252.
21. Colovic M, Dimitrijevic M, Sonnenburg C, et al. Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematol J 2003;4:358-362.
22. Dan K, Gomi S, Kuramoto A, et al. A multicenter prospective study on the treatment of chronic idiopathic thrombocytopenic purpura. Int J Hematol 1992;55:287-292.
23. Mehta JB, Singhal SB, Mehta BC. Intravenous immunoglobulin therapy of immune thrombocytopenia. J Assoc Physicians India 1992;40:340-342.
24. Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomised, multicentre trial. Lancet 2002;359:23-29.
25. Bussel JB, Eldor A, Kelton JG, et al. IGIV-C, a novel intravenous immunoglobulin: Evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thromb Haemost 2004;91:771-778.
26. Newland AC, Burton I, Cavenagh JD, et al. Vigam-S, a solvent/detergent- treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura. Transfus Med 2001;11:37-44.
27. Wolf HH, Davies SV, Borte M, et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: Studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sang 2003;84:45-53.
28. Arnal C, Piette JC, Leone J, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002;29:75-83.
29. Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: Analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004;83:254-263.
30. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
31. Uchino H, Yasunaga K, Akatsuka J. A cooperative clinical trial of high-dose immunoglobulin therapy in 177 cases of idiopathic thrombocytopenic purpura. Thromb Haemost 1984;51:182-185.
32. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003;349:831-836,